ABH Healthcare Ltd IPO
Status: Closed
Overview
IPO date
24 Aug 2026 to 27 Aug 2026
Face value
₹ 10 per share
Price
₹ 96 to ₹102 per share
Issue Size
3,429,600 shares
(aggregating up to ₹ 34.98 Cr)
(aggregating up to ₹ 34.98 Cr)
Allotment Date
28 Aug 2026
Listing at
NSE
Issue type
Book Building - SME
Sector
Healthcare
Unlock Stock of the Month
T&C*
Strengths vs Risks of ABH Healthcare Ltd
Know the pros & cons
Strengths
- Doctor led professional management team with proven execution capabilities.
- Delivering quality clinical care by attracting and retaining experienced and renowned clinicians.
- Diversified operations across clinical specialties, payor mix and hospitals.
- Robust operating infrastructure including information technology and modern equipments.
- Track record of stable operating and financial performance and growth.
Risks
- The Company has been specifically formed for the purpose of acquisition of the business of Anil Baghi Hospital (sole proprietorship concern of one of its Promoters), thus the company has limited operating history as a Company which may make it difficult for investors to evaluate the company's historical performance or future prospects.
- The company's revenue is significantly dependent on its only hospital in Ferozepur, Punjab, any change in the economic or political circumstances in or around the areas of Ferozepur, could materially affect the company's business, financial condition and results of operations.
- If the company is unable to keep pace with technological changes, new equipments and service introductions, changes in patients' needs and evolving industry standards as well as failures or malfunction of its medical or other equipments, the company's business and financial condition may be adversely affected.
- The company relies on certain third parties, including suppliers, and also enters into contracts with third-party payers such as insurance companies, third party administrators, corporations and government departments. Termination, nonrenewal or any breach of the conditions of such contracts could have a material adverse impact on the company's business, financial condition and results of operations.
- The company operates in a highly regulated industry, and compliance with applicable safety, health, environmental and other governmental regulations and any violations of existing regulations may adversely affect its business, results of operations and cash flows.
- The Company has acquired Anil Baghi Hospital, the sole proprietorship concern of one of its Promoters after its incorporation vide Business Transfer Agreement dated March 16, 2022. Any future acquisition of other businesses could result in operating difficulties, integration issues and other adverse consequences due to the company's limited past experience in businesses.
- The object of making unidentified acquisitions may lead to significant investments in the businesses that may not be sustainable in the long run, which may result in financial losses and negatively impact the company's overall portfolio.
- The company does not own the premises where its Registered office and hospital are located. Any adverse event that requires it to vacate the said property may materially adversely affect the company's business operations and financial conditions.
- The company has a high debt-equity ratio and may faces certain funding risks. Any further increase in borrowings may have a material adverse effect on the company's business, financial condition and results of operations. Further, if the company does not generate sufficient amount of cash flow from operations, its liquidity and ability to service the company's indebtedness could be adversely affected.
- The company is exposed to legal claims and regulatory actions arising from the provision of healthcare services and may be subject to liabilities arising from claims of malpractice and medical negligence which could materially and adversely affect its reputation and prospects.
- If the company fails to achieve favorable pricing on medical consumables, pharmacy items, drugs, and surgical instruments from its suppliers or is unable to pass on any cost increases to its payers, and other adverse regulatory changes in the healthcare industry the company's profitability could be materially and adversely affected.
- The company's arrangements with some of its doctors may give rise to conflicts of interest and time-allocation constraints, adversely affecting the company's operations.
- The company has unsecured loans from its Promoters, ICDs from third party lenders, which are repayable on demand. Any demand from lenders for repayment of such unsecured loans, may adversely affect the company's business operations.
- If the company is unable to increase its hospital occupancy rates and reduce average length of stay of the company's patient, its may not be able to generate adequate returns on the company's capital expenditure.
- Most of the company's diagnostic imaging equipment contain radiation during operation which could make it liable for damages.
- The company's business requires it to obtain and renew certain registrations, licenses, approvals, NoCs and permits in the ordinary course of the company's business. Its inability to obtain, renew or maintain the company's statutory and regulatory permits and approvals required to operates its business may have a material adverse effect on the company's business, financial condition and results of operations.
- The Company, its Director and its Promoters and Controlled Entities are party to certain litigation and claims. Any adverse decision may make it liable to liabilities/penalties and may adversely affect the company's reputation, business and financial status.
- The company's lenders have charge over its movable and immovable properties in respect of finance availed by it.
- The company has incurred borrowings from commercial banks, NBFCs, Financial Institutions and any non-compliance with repayment and other covenants in the company's financing agreements could adversely affect its business and financial condition.
- The company's ability to provide affordable healthcare depends on the maintenance of a high volume of patients, occupancy rates, managing operating and project costs and effective capital management. Any increase in such costs could adversely affect its business, financial condition and results of operations.
- The company derives a significant portion of its revenues from the company's tie up arrangements with Governmental organizations, insurance companies, third party administrators and corporations. The loss of any one or more of its major customers would have a material effect on the company's business operations and profitability.
- The company has certain commitments and contingent liabilities that may adversely affect its financial condition.
- The company faces competition from other hospitals and healthcare facilities. If the company is unable to compete effectively, its business and results of operations may be materially and adversely affected.
- The company's funding requirements and proposed deployment of the Net Proceeds are based on management estimates and have not been independently appraised by any bank or financial institution or any other independent agency and may be subject to change based on various factors, some of which are beyond its control. Any variation in the utilization of the Net Proceeds or in the terms of the conditions as disclosed in this Red Herring Prospectus would be subject to certain compliance requirements, including prior shareholders' approval, and the company's business, financial condition and results of operations may be adversely affected.
- The company has not been able to obtain certain records of educational qualifications and experience certificates of Directors, and has relied on the affidavit furnished by them for such details of their profile, included in this Red Herring Prospectus.
- The company is dependent on certain field of specialty for a substantial portion of its revenue, i.e., internal medicine, cardiology, neuro surgery, orthopedics/joint replacement/trauma and general surgery. Any material impact on the company's earnings from these fields will impact its financial condition and results of operations significantly.
- The company is required to handle personal information, including medical data, as a result of which its could faces breach or theft of confidential and other sensitive information of the company's patients or procedures or any kind of data leakage in the past, any breach of its confidentiality obligations to the company's patients, including due to data leakages or improper use of such medical information. This could expose it to fines, potential liabilities and legal proceedings, such as litigation or regulatory proceedings, which would adversely impact the company's reputation.
- Pricing regulations and reforms in the healthcare industry and the uncertainty associated with pharmaceutical pricing and other matters could adversely affect the company's business, results of operations and cash flows.
- The company is vulnerable to failures of its information technology system, which could adversely affect its business.
- The company's hospitals are susceptible to risks arising on account of fire and other incidents. This may materially and adversely affect its business, cash flows, financial condition, and results of operations.
- The company may be subject to worker unrests and increased wages expenses which could materially and adversely affect the company's business, financial condition, results of operations and cash flows.
- The company's operations are subject to high working capital requirements. Its inability to maintain an optimal level of working capital required for the company's business may impact its operations adversely.
- The company's insurance coverage may not adequately protect it against potential risk, and this may have a material adverse effect on the company's business.
- The company's Promoters and Promoter Group will be able to exercise significant influence and control over its operations after the issue and may have interests that are different from those of the company's other shareholders.
- The company has negative cash flows during certain fiscal years in relation to its operating and investing activities. Sustained negative cash flows in the future would adversely affect the company's results of operations and financial condition.
- The company has in the past entered into related party transactions and may continue to do so in the future, which may potentially involve conflicts of interest with its shareholders and Directors.
- There are certain discrepancies and non-compliances noticed in some of the company's financial reporting and/or records relating to the filing of returns and deposit of statutory dues with the taxation and other statutory authorities.
- The company's Promoters and Directors have interests in entities, which are in businesses similar to its and this may result in potential conflict of interest with it.
- The company's Promoters and member of Promoter Group are co-borrowers and have provided personal guarantee for loans availed by it.
- The company may be unable to detect, deter and prevent all instances of fraud or negligence or other misconduct committed by the company's employees or other third parties, which may have a material adverse effect on its business, results of operations and financial condition.
- Inability to maintain adequate internal controls may affect the company's ability to effectively manage its operations, resulting in errors or information lapses.
- Some of the company's Promoters as well as some Directors on its Board and their relatives hold Equity Shares and are therefore interested in the Company's performance in addition to their remuneration and reimbursement of expenses.
- Industry information included in this Red Herring Prospectus has been derived from industry sources. There can be no assurance that such third-party statistical, financial and other industry information is complete, reliable or accurate. Further, neither the company's nor the BRLM have independently verified certain data in this Red Herring Prospectus.
- The company's indebtedness and the conditions and restrictions imposed by its financing arrangements may limit the company's ability to grow its business and adversely impact the company's business.
- The company's ability to pay dividends in the future will depends on its earnings, financial condition, working capital requirements, capital expenditures and restrictive covenants of the company's financing arrangements.
- The company may be unable to sufficiently obtain, maintain, protect, or enforce its intellectual property and other proprietary rights.
- The company has had instances of regulatory non-compliances, including certain lapses in relation to regulatory filings, internal controls and internal record keeping under applicable company law.
- There is no monitoring agency appointed by the Company to monitor the utilization of the Issue proceeds.
- The average cost of acquisition of Equity Shares for the company's Promoters may be lower than the Issue Price.
- The Equity Shares has never been publicly traded, and, after the Issue, the Equity Shares may experience price and volume fluctuations, and an active trading market for the Equity Shares may not develop. Further, the price of the Equity Shares may be volatile, and you may be unable to resell the Equity Shares at or above the Issue Price, or at all.
- Certain key performance indicators for certain listed industry peers included in this Red Herring Prospectus have been sourced from public sources and there is no assurance that such financial and other industry information is complete.
- Certain corporate records of entities from which the company's Promoters have disassociated are not traceable. Additionally, some of the constitutional documents of Promoter Group entities cannot be traced.
- In the event there is any delay in the completion of the Issue, there would be a corresponding delay in the completion of the objects/schedule of implementation of Net Proceeds which would in turn affect the company's revenue and results of operations.
- There is no guarantee that the company's Equity Shares will be listed on the Stock Exchanges in a timely manner or at all.
- The company has not identified any alternate source of raising the funds required for the object of the Issue and the deployment of funds is entirely at its discretion and as per the details mentioned in the section titled "Objects of the Issue".
- There are restrictions on daily movements in the trading price of the Equity Shares, which may adversely affect a shareholder's ability to sell Equity Shares or the price at which Equity Shares can be sold at a particular point in time.
- None of the company's Directors has any prior experience of being a Director in any other listed Company in India.
ABH Healthcare Ltd Peer Comparison
Understand the company’s industry standing
ABH Healthcare Limited
Sangani Hospitals Limited
Maitreya Medicare Limited
Face Value
10
10
10
Standalone / Consolidated
Consolidated
Consolidated
Consolidated
Total Income Rs. Cr.
52.5069
106.9581
44.8499
EPS-Basis
7.05
2.17
-3.64
EPS-Diluted
7.05
2.17
-3.64
NAV Per Share
21.58
23.3
42.67
P/E-Basic EPS
14.47
23.66
-32.68
P/E-Diluted EPS
---
---
---
RONW(%)
39.07
16.2
-8.1
Latest NAV Period
---
---
---
Latest NAV
---
---
---
How to check the allotment status of ABH Healthcare Ltd IPO?
Follow the steps
Open link to the registrar using this URL (https://evault.kfintech.com/ipostatus/).
Select company from dropdown menu.
Enter details- PAN, Application number or DP client ID
Get your allotment status
Open link to the registrar using this URL (https://evault.kfintech.com/ipostatus/).
IPO reads
Stay updated with the latest IPO developments
February 27, 2025 | 5 min read
₹50.11 Cr Balaji Phosphates IPO Opens Feb 28. Issue Details and SWOT AnalysisRead More
February 25, 2025 | 5 min read
Tata Capital Board Approves ₹15,000 Cr Plus Mega IPO; Tata Investment Shares Soar 8%Read More
February 18, 2025 | 5 min read
Busy Week Ahead: 2 SME IPOs and 9 Market Listings – Get the Complete Details HereRead More
October 25, 2024 | 5 min read
Waaree Energies IPO: GMP Soars 106% Amid 76.34x Subscription – Check Your Allotment Status!Read More
October 22, 2024 | 5 min read
Upcoming IPOs: 9 Public Issues Set to Raise ₹10,984.8 Cr – Key Insights Inside!Read More
October 17, 2024 | 5 min read
Hyundai IPO Hits a Speed Bump With 42% Subscription On Day 2 : 4 Reasons WhyRead More
September 6, 2024 | 5 min read
Bajaj Housing Finance IPO: All You Need to KnowRead MoreOctober 17, 2024 | 5 min read
Hyundai IPO Hits a Speed Bump With 42% Subscription On Day 2 : 4 Reasons WhyRead More
August 26, 2024 | 5 min read
Premier Energies IPO: Key Details Ahead of the ₹2,830.40 Cr Issue LaunchRead MoreMore on IPOs
Navigate your way to other IPO resources
Latest videos on IPOs
IPO highlights & details!
FAQs on IPO
Get answers to all your questions here!
The IPO opens on 24 Aug 2026 & closes on 27 Aug 2026.
ABH Healthcare Limited was originally incorporated as a private limited company in the name and style of 'ABH Healthcare Private Limited' vide certificate of incorporation dated March 2, 2021 issued by Registrar of Companies, Central Registration Centre. Further, Company acquired the sole Proprietorship Concern of Dr. Kamal Baghi, our Promoter in the name 'Anil Baghi Hospital' via Business Transfer Agreement dated March 16, 2022. Subsequently, it was converted from a private Company to a public Company and the name was changed to 'ABH Healthcare Limited', and a fresh Certificate of incorporation dated November 15, 2024 was issued by the Registrar of Companies, Chandigarh.
The Company operate hospital under the 'Anil Baghi Hospital' brand, honoring the sacrifice of late Shri Anil Baghi. Located in Ferozepur, Punjab, hospital has a capacity of 150 beds. Acquired by the Company in 2022, the hospital was established in 1985 with 30 beds and is driven by a vision to provide affordable, accessible, and high-quality healthcare services. Since the acquisition, Company consistently invested in the hospital, expanding bed capacity, increasing the workforce, and introducing additional services and clinical specialties. It offer 25 medical specialties such as, cardiac sciences, neurology, minimally invasive spine and brain surgeries, medical and surgical gastroenterology, laparoscopic and bariatric surgery, urology, pulmonology, nephrology, ENT, maxillofacial surgeries, obstetrics and gynecology, orthopedics and joint replacement, neuropsychiatry, adult and neonatal critical care and drug de-addiction, general surgery, physiotherapy, dentistry, radiology, etc.
Presently, Company is engaged in establishing, maintaining, assisting healthcare services in India, in the form of Super Speciality Hospitals and Allied Services such as Laboratories & Diagnostic Centres, Blood Bank and other related services. It works 150 beds, including 70 ICU beds, 10 pediatrics units, 7 emergency units, 10 dialysis bed (includes beds provided to Five Creeks Healthcare LLP), through the dialysis unit.
Company is planning the initial public offer of 34,29,000 Equity Shares of face value Rs 10 through fresh Issue.
ABH Healthcare Ltd IPO will close on 27 Aug 2026.
- Doctor led professional management team with proven execution capabilities.
- Delivering quality clinical care by attracting and retaining experienced and renowned clinicians.
- Diversified operations across clinical specialties, payor mix and hospitals.
- Robust operating infrastructure including information technology and modern equipments.
- Track record of stable operating and financial performance and growth.
| S.No | Promoters Name | Pre Issue Shares | Pre Issue Percentage | Post Issue Shares | Post Issue Percentage |
|---|---|---|---|---|---|
| 1 | Kamal Baghi | 2399984 | 30 | 2399984 | 21 |
| 2 | Saurabh Baghi | 5480000 | 68.5 | 5480000 | 47.95 |
| 3 | Vaishali Saini | 120000 | 1.5 | 120000 | 1.05 |
| 4 | Hemraj Saini | 4 | --- | 4 | --- |
| 5 | Rita Saini | 4 | --- | 4 | --- |
| 6 | Sukarma Khanna | 4 | --- | 4 | --- |
- The Company has been specifically formed for the purpose of acquisition of the business of Anil Baghi Hospital (sole proprietorship concern of one of its Promoters), thus the company has limited operating history as a Company which may make it difficult for investors to evaluate the company's historical performance or future prospects.
- The company's revenue is significantly dependent on its only hospital in Ferozepur, Punjab, any change in the economic or political circumstances in or around the areas of Ferozepur, could materially affect the company's business, financial condition and results of operations.
- If the company is unable to keep pace with technological changes, new equipments and service introductions, changes in patients' needs and evolving industry standards as well as failures or malfunction of its medical or other equipments, the company's business and financial condition may be adversely affected.
- The company relies on certain third parties, including suppliers, and also enters into contracts with third-party payers such as insurance companies, third party administrators, corporations and government departments. Termination, nonrenewal or any breach of the conditions of such contracts could have a material adverse impact on the company's business, financial condition and results of operations.
- The company operates in a highly regulated industry, and compliance with applicable safety, health, environmental and other governmental regulations and any violations of existing regulations may adversely affect its business, results of operations and cash flows.
- The Company has acquired Anil Baghi Hospital, the sole proprietorship concern of one of its Promoters after its incorporation vide Business Transfer Agreement dated March 16, 2022. Any future acquisition of other businesses could result in operating difficulties, integration issues and other adverse consequences due to the company's limited past experience in businesses.
- The object of making unidentified acquisitions may lead to significant investments in the businesses that may not be sustainable in the long run, which may result in financial losses and negatively impact the company's overall portfolio.
- The company does not own the premises where its Registered office and hospital are located. Any adverse event that requires it to vacate the said property may materially adversely affect the company's business operations and financial conditions.
- The company has a high debt-equity ratio and may faces certain funding risks. Any further increase in borrowings may have a material adverse effect on the company's business, financial condition and results of operations. Further, if the company does not generate sufficient amount of cash flow from operations, its liquidity and ability to service the company's indebtedness could be adversely affected.
- The company is exposed to legal claims and regulatory actions arising from the provision of healthcare services and may be subject to liabilities arising from claims of malpractice and medical negligence which could materially and adversely affect its reputation and prospects.
- If the company fails to achieve favorable pricing on medical consumables, pharmacy items, drugs, and surgical instruments from its suppliers or is unable to pass on any cost increases to its payers, and other adverse regulatory changes in the healthcare industry the company's profitability could be materially and adversely affected.
- The company's arrangements with some of its doctors may give rise to conflicts of interest and time-allocation constraints, adversely affecting the company's operations.
- The company has unsecured loans from its Promoters, ICDs from third party lenders, which are repayable on demand. Any demand from lenders for repayment of such unsecured loans, may adversely affect the company's business operations.
- If the company is unable to increase its hospital occupancy rates and reduce average length of stay of the company's patient, its may not be able to generate adequate returns on the company's capital expenditure.
- Most of the company's diagnostic imaging equipment contain radiation during operation which could make it liable for damages.
- The company's business requires it to obtain and renew certain registrations, licenses, approvals, NoCs and permits in the ordinary course of the company's business. Its inability to obtain, renew or maintain the company's statutory and regulatory permits and approvals required to operates its business may have a material adverse effect on the company's business, financial condition and results of operations.
- The Company, its Director and its Promoters and Controlled Entities are party to certain litigation and claims. Any adverse decision may make it liable to liabilities/penalties and may adversely affect the company's reputation, business and financial status.
- The company's lenders have charge over its movable and immovable properties in respect of finance availed by it.
- The company has incurred borrowings from commercial banks, NBFCs, Financial Institutions and any non-compliance with repayment and other covenants in the company's financing agreements could adversely affect its business and financial condition.
- The company's ability to provide affordable healthcare depends on the maintenance of a high volume of patients, occupancy rates, managing operating and project costs and effective capital management. Any increase in such costs could adversely affect its business, financial condition and results of operations.
- The company derives a significant portion of its revenues from the company's tie up arrangements with Governmental organizations, insurance companies, third party administrators and corporations. The loss of any one or more of its major customers would have a material effect on the company's business operations and profitability.
- The company has certain commitments and contingent liabilities that may adversely affect its financial condition.
- The company faces competition from other hospitals and healthcare facilities. If the company is unable to compete effectively, its business and results of operations may be materially and adversely affected.
- The company's funding requirements and proposed deployment of the Net Proceeds are based on management estimates and have not been independently appraised by any bank or financial institution or any other independent agency and may be subject to change based on various factors, some of which are beyond its control. Any variation in the utilization of the Net Proceeds or in the terms of the conditions as disclosed in this Red Herring Prospectus would be subject to certain compliance requirements, including prior shareholders' approval, and the company's business, financial condition and results of operations may be adversely affected.
- The company has not been able to obtain certain records of educational qualifications and experience certificates of Directors, and has relied on the affidavit furnished by them for such details of their profile, included in this Red Herring Prospectus.
- The company is dependent on certain field of specialty for a substantial portion of its revenue, i.e., internal medicine, cardiology, neuro surgery, orthopedics/joint replacement/trauma and general surgery. Any material impact on the company's earnings from these fields will impact its financial condition and results of operations significantly.
- The company is required to handle personal information, including medical data, as a result of which its could faces breach or theft of confidential and other sensitive information of the company's patients or procedures or any kind of data leakage in the past, any breach of its confidentiality obligations to the company's patients, including due to data leakages or improper use of such medical information. This could expose it to fines, potential liabilities and legal proceedings, such as litigation or regulatory proceedings, which would adversely impact the company's reputation.
- Pricing regulations and reforms in the healthcare industry and the uncertainty associated with pharmaceutical pricing and other matters could adversely affect the company's business, results of operations and cash flows.
- The company is vulnerable to failures of its information technology system, which could adversely affect its business.
- The company's hospitals are susceptible to risks arising on account of fire and other incidents. This may materially and adversely affect its business, cash flows, financial condition, and results of operations.
- The company may be subject to worker unrests and increased wages expenses which could materially and adversely affect the company's business, financial condition, results of operations and cash flows.
- The company's operations are subject to high working capital requirements. Its inability to maintain an optimal level of working capital required for the company's business may impact its operations adversely.
- The company's insurance coverage may not adequately protect it against potential risk, and this may have a material adverse effect on the company's business.
- The company's Promoters and Promoter Group will be able to exercise significant influence and control over its operations after the issue and may have interests that are different from those of the company's other shareholders.
- The company has negative cash flows during certain fiscal years in relation to its operating and investing activities. Sustained negative cash flows in the future would adversely affect the company's results of operations and financial condition.
- The company has in the past entered into related party transactions and may continue to do so in the future, which may potentially involve conflicts of interest with its shareholders and Directors.
- There are certain discrepancies and non-compliances noticed in some of the company's financial reporting and/or records relating to the filing of returns and deposit of statutory dues with the taxation and other statutory authorities.
- The company's Promoters and Directors have interests in entities, which are in businesses similar to its and this may result in potential conflict of interest with it.
- The company's Promoters and member of Promoter Group are co-borrowers and have provided personal guarantee for loans availed by it.
- The company may be unable to detect, deter and prevent all instances of fraud or negligence or other misconduct committed by the company's employees or other third parties, which may have a material adverse effect on its business, results of operations and financial condition.
- Inability to maintain adequate internal controls may affect the company's ability to effectively manage its operations, resulting in errors or information lapses.
- Some of the company's Promoters as well as some Directors on its Board and their relatives hold Equity Shares and are therefore interested in the Company's performance in addition to their remuneration and reimbursement of expenses.
- Industry information included in this Red Herring Prospectus has been derived from industry sources. There can be no assurance that such third-party statistical, financial and other industry information is complete, reliable or accurate. Further, neither the company's nor the BRLM have independently verified certain data in this Red Herring Prospectus.
- The company's indebtedness and the conditions and restrictions imposed by its financing arrangements may limit the company's ability to grow its business and adversely impact the company's business.
- The company's ability to pay dividends in the future will depends on its earnings, financial condition, working capital requirements, capital expenditures and restrictive covenants of the company's financing arrangements.
- The company may be unable to sufficiently obtain, maintain, protect, or enforce its intellectual property and other proprietary rights.
- The company has had instances of regulatory non-compliances, including certain lapses in relation to regulatory filings, internal controls and internal record keeping under applicable company law.
- There is no monitoring agency appointed by the Company to monitor the utilization of the Issue proceeds.
- The average cost of acquisition of Equity Shares for the company's Promoters may be lower than the Issue Price.
- The Equity Shares has never been publicly traded, and, after the Issue, the Equity Shares may experience price and volume fluctuations, and an active trading market for the Equity Shares may not develop. Further, the price of the Equity Shares may be volatile, and you may be unable to resell the Equity Shares at or above the Issue Price, or at all.
- Certain key performance indicators for certain listed industry peers included in this Red Herring Prospectus have been sourced from public sources and there is no assurance that such financial and other industry information is complete.
- Certain corporate records of entities from which the company's Promoters have disassociated are not traceable. Additionally, some of the constitutional documents of Promoter Group entities cannot be traced.
- In the event there is any delay in the completion of the Issue, there would be a corresponding delay in the completion of the objects/schedule of implementation of Net Proceeds which would in turn affect the company's revenue and results of operations.
- There is no guarantee that the company's Equity Shares will be listed on the Stock Exchanges in a timely manner or at all.
- The company has not identified any alternate source of raising the funds required for the object of the Issue and the deployment of funds is entirely at its discretion and as per the details mentioned in the section titled "Objects of the Issue".
- There are restrictions on daily movements in the trading price of the Equity Shares, which may adversely affect a shareholder's ability to sell Equity Shares or the price at which Equity Shares can be sold at a particular point in time.
- None of the company's Directors has any prior experience of being a Director in any other listed Company in India.
The Issue type of ABH Healthcare Ltd is Book Building - SME.
The minimum application for shares of ABH Healthcare Ltd is 2400.
The total shares issue of ABH Healthcare Ltd is 3429600.
Initial public issue of 34,29,600 equity shares of face value of Rs. 10/- each ("Equity Shares") of ABH Healthcare Limited ("The Company" or the "Issuer") for cash at a price of Rs. 102 per equity share (Including a Securities Premium of Rs. 92 per equity share) ("Issue Price"), aggregating to Rs. 34.98 Crores (the "Issue"), of which 1,72,800 equity shares of face value of Rs.10/- each for cash at a price of Rs. 102 per equity share including a securities premium of Rs. 92 per equity share aggregating to Rs. 1.76 Crores will be reserved for subscription by market maker ("Market Maker Reservation Portion"). The issue less the market maker reservation portion i.e. Issue of 32,56,800 equity shares of face value of Rs.10/- each at an issue price of Rs. 102 per equity share aggregating to Rs. 33.22 Crores is hereinafter referred to as the "Net Issue". The issue and the net issue will constitute 30.01% and 28.49% respectively of the post issue paid-up equity share capital of the company.
Price Band: Rs. 102 per equity share of face value of Rs. 10/- each.
The floor price is 10.20 times the face value of the equity shares.
Bids can be made for a minimum of 2,400 equity shares and in multiples of 1,200 equity shares thereafter.